Targeting a master regulator of tumour cell plasticity as a new adjuvant therapy for prostate cancer

针对肿瘤细胞可塑性的主要调节因子作为前列腺癌的新辅助疗法

• 批准号: nhmrc : GNT1100417
• 负责人: Dr Brett Hollier
• 金额: $ 78.03万
• 依托单位: Queensland University of Technology
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-master-regulator-prostate-cancer/1346118
• 关键词: Targeting; master; regulator; tumour; cell

Prostate cancer (PCa) claims the lives of over 3,000 Australian men each year. This highlights the urgent need to identify new molecular targets that can be developed as additional therapies for men with PCa. Our team has identified the protein, Zeb1, to be highly expressed in aggressive and treatment resistant forms of PCa. This study aims to characterise the role of Zeb1 in the lethal progression of PCa and to develop a new therapeutic agent to inhibit the production of ZEB1 by cancer cells.

前列腺癌（PCa）每年夺去3000多名澳大利亚男性的生命。这强调了迫切需要确定新的分子靶点，可以开发为男性前列腺癌的额外治疗。我们的团队已经确定了Zeb1蛋白在侵袭性和耐药形式的PCa中高度表达。本研究旨在描述Zeb1在PCa致死性进展中的作用，并开发一种新的治疗药物来抑制癌细胞产生Zeb1。